Press Releases: Molecular Imaging

Select a different year:

Siemens Announces First Integrated Amyloid Imaging Solution in the U.S. Market for Use in Evaluation of Alzheimer’s Disease and Other Causes of Cognitive Decline

April 10, 2012

Hoffman Estates, Ill., April 10, 2012 — Siemens Healthcare is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques — one of the necessary pathological features of Alzheimer’s disease¹,²,³ — in the living brain. The latest elements of Siemens’ integrated solution came today with the company’s U.S. Food and Drug Administration (FDA) 510(k) application for its syngo®.PET Amyloid Plaque⁴ proprietary neurology quantification software, as well as the recent FDA approval of Eli Lilly and Company’s Amyvid™ (Florbetapir F 18 Injection), a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.⁵ More

Siemens Outlines Solutions for Sustainable Cardiovascular Care at ACC ’12

March 22, 2012

Chicago, March 22, 2012 – At the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC), March 24-27 in Chicago, Siemens Healthcare (booth #2026) will offer solutions for sustainable cardiovascular care to help ensure that cardiovascular professionals are “in it for the long run” – the theme of this year’s Siemens booth. Providing a comprehensive portfolio of systems and support solutions that range from imaging modalities to information technology (IT) and in vitro diagnostics, Siemens is uniquely positioned to aid the cardiovascular community in making sound clinical decisions, providing safer procedures, improving operational efficiency, and maximizing its investments in healthcare technology and IT – ultimately helping to make the delivery of cardiovascular care more sustainable. More

Siemens’ New Biograph mCT PET•CT System Receives FDA Clearance

February 15, 2012

Malvern, Pa., February 15, 2012 – Siemens Healthcare has announced that the Food and Drug Administration (FDA) recently cleared the features associated with the new Biograph mCT positron emission tomography/computed tomography (PET•CT) scanner. The new Biograph mCT enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). Technological innovations and intelligent software solutions within the new PET•CT result in accurate, consistent quantitative assessments. With the new Biograph mCT, which was unveiled last November at the 2011 annual meeting of the Radiological Society of North America (RSNA) in Chicago, Siemens offers yet another paradigm in PET•CT, bolstering the company’s innovative power and competitiveness – a goal of its recently announced global initiative, Agenda 2013. More